Maker of a Parkinson's therapy grown from patients' own cells raises $140.6M

Aspen Neuroscience, a San Diego company developing a Parkinson’s disease treatment grown from each patient’s own cells, has raised about $140.6 million by selling shares on the Nasdaq stock market.¹ The company priced 9,375,000 shares at $15.00 each, and the stock was scheduled to start trading on October 30, 2026, under the symbol “ASPE.”¹ The money comes as the company’s only treatment in human testing is still in a small, early safety trial with no results posted yet.²

What happened

An initial public offering, or IPO, is the first time a private company sells shares to the public. Aspen’s offering was priced at $15.00 per share, with expected gross proceeds of about $140.6 million before underwriting discounts and commissions (the fees paid to the banks that run the sale).¹ All of the shares were sold by Aspen itself, with no existing shareholders selling in this part of the deal.¹

The shares are listed on the Nasdaq Global Select Market, and the sale was expected to close on November 2, 2026, subject to the usual conditions.¹ Aspen also gave the banks a 30-day option to buy up to 1,406,250 more shares at the same price, which could raise more money if used.¹ Five banks led the deal: Leerink Partners, Piper Sandler, Stifel, UBS Investment Bank and Oppenheimer & Co.¹ The company’s registration statement with the U.S. Securities and Exchange Commission, the government agency that oversees stock sales, became effective on October 29, 2026.¹

The report Biohack read on the offering does not say how Aspen plans to spend the money. It describes the company as clinical-stage, meaning it has a treatment in human trials but nothing approved for sale.¹ That report was itself generated by AI from financial data, and its publisher says it is not liable for inaccuracies.¹

What the treatment is

Aspen’s lead product is called sasineprocel. It is described as an experimental, single-dose cell therapy made from the patient’s own cells, using induced pluripotent stem cells (iPSCs): ordinary adult cells that are reprogrammed in the lab so they can become almost any cell type.¹ In the human trial the product goes by its earlier code name, ANPD001.²

Parkinson’s disease involves the loss of brain cells that make dopamine, a chemical messenger that helps control movement. Aspen’s approach aims to replace them. According to a report on the company’s lab work, the process starts with a small skin punch biopsy. Those skin cells are reprogrammed into stem cells, then grown into early-stage dopamine nerve cells, which are delivered with image guidance into the putamen, a brain area involved in movement.¹

Because the cells come from the patient, every dose is made for one person. The trial registry states that all participants have their cells manufactured from their own previously collected cells.²

The evidence so far

The only human study listed is an early trial that began on January 23, 2024.² It is a “Phase 1/2a dose escalation” study: an early test, mainly for safety, in which different groups may receive different amounts of cells. The registry lists an estimated 9 participants.² Its main measure is how often side effects occur and how severe they are over the first year.² The registry estimates the main data collection will finish around March 30, 2027, and shows no results posted yet.²

Patients have the cells implanted by surgery under general anesthesia.³ They are then followed for 5 years for effects on symptoms, safety and whether the cells survive, using MRI and PET brain scans, and then checked by phone once a year for another 10 years, for 15 years of follow-up in total.³ The full study is expected to end around April 2030.³ Sites include UCSF in San Francisco and the University of California, Los Angeles.³

The trial is not open to the general public. It is enrolling by invitation only, for people aged 40 to 75 who were already part of a separate “trial-ready” group, have had Parkinson’s for at least 4 years and respond clearly to levodopa, a standard Parkinson’s drug.³ People who have had deep brain stimulation, focused ultrasound, gene therapy or other treatments inside the skull for Parkinson’s are excluded, as are people with dementia or memory problems.³

Animal and lab work

Before the human trial, Aspen ran studies in animals. A report on a paper published in the journal Cell Stem Cell in September 2026 says studies in animal models of Parkinson’s showed improved movement, and a nine-month safety study in rodents found no treatment-related harmful findings.¹ The same paper described quality checks, including whole-genome sequencing and a company tool called NeuriTest that uses machine learning to judge whether each patient’s batch of cells looks like it should.¹ These are animal and lab results; they do not show what happens in people.

A 2024 study in monkeys, listed in the company’s publication record, tested a new surgical route for placing the cells in nine macaques.⁴ The researchers reported that the approach hit the target area in all animals and that all survived to the planned end of the study. The first 4 animals had mild brain swelling at the end of surgery, and 3 of them had temporary reduced vision; changes to drugs and fluids during surgery addressed these problems.⁴

What this does not show yet

The share sale is a financial event. It does not add any new information about whether the treatment is safe or helps people with Parkinson’s. No human results from the trial have been posted to the public registry.²

The sources also disagree on how far along the treatment is. The report on the September paper says sasineprocel “enters Phase 3,” the large final stage of testing before approval.¹ Yet the same report says the animal results supported moving into the “ongoing Phase 1/2a ASPIRO clinical trial.”¹ The public trial registry lists the human study as an early-stage trial still enrolling by invitation², and a drug database updated October 14, 2026, lists Phase 1 as the treatment’s highest stage.⁴ Biohack found no registry record of a larger trial in the sources it read.

The early trial is also small and has no comparison group listed in the registry summary, so even when results come out, they will mainly speak to safety rather than proving benefit.²

Who is behind it

Aspen Neuroscience was founded in 2018 in California and has between 100 and 250 employees, according to a company database.⁴ It sponsors the human trial.² Besides its lead treatment, the database lists two programs still in lab testing: ANPD-003 for Parkinson’s and ANPD-004 for rare diseases, and it tags the company with gene editing work.⁴ The company’s chief scientific officer is Xiaokui Zhang, who said combining genetic analysis with lab testing helps judge the quality of each cell batch.¹

The animal results and the descriptions of the treatment come from the company’s own research and from reports based on its announcements. Independent researchers’ views of the work were not part of the sources Biohack read.

How it fits the field

Replacing lost dopamine cells is one of several ways researchers are trying to treat Parkinson’s beyond today’s drugs. Aspen’s version stands out because each dose is made from the patient’s own cells rather than from a shared, ready-made cell line.¹ This means making a separate batch for every patient, which is why the company stresses its quality checks.¹ Whether this personal approach brings practical advantages in people has not yet been shown in published human data.

What to watch next

• Whether the banks use their option to buy the extra 1,406,250 shares within 30 days.¹
• Any statement from Aspen on how the money will be spent across its programs.
• First safety results from the 9-person trial, with main data collection estimated to end in March 2027.²
• Any registered plan for a larger trial, which would clear up the conflicting reports about how far along the treatment is.